Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...
Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%31-34; PanOptix® Trifocal IOL, implanted over 2.2 ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc. (NYSE:ALC) announced the approval of the Clareon PanOptix Pro intraocular lens for patients in ...
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results